Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 August 2024 | Story André Damons | Photo Supplied
Maricel-van-Rooyen
Maricél van Rooyen, Project Manager for Research Information Management System (RIMS) and Research Ethics Adviser in the Directorate Research Development (DRD) at the University of the Free State (UFS), is the Programme Coordinator for a first-of-its-kind Southern African Research and Innovation Management Association (SARIMA)/ COP webinar on Environment and Biosafety Research Ethics.

The University of the Free State (UFS) is playing host to a first-of-its-kind webinar on Environment and Biosafety Research Ethics later this month with Maricél van Rooyen, Project Manager for Research Information Management System (RIMS) and Research Ethics Adviser in the Directorate Research Development (DRD), playing a pivotal role.

The webinar, which is part of the Eastern Region Community of Practice (COP), is taking place on 20 August. The target market for this virtual workshop is Biosafety and Environmental Research Ethics Committee (REC) chairpersons and members, professionals including research management professionals, administrators, research compliance managers and advisers, and research directors in Southern Africa and beyond.

Van Rooyen will be the Programme Coordinator for this Southern African Research and Innovation Management Association (SARIMA)/ COP Research Ethics Webinar, while Prof Robert Bragg, chairperson of the UFS Environmental and Biological Research Ethics Committee (EBREC), will give a presentation on the establishment of an EBREC.

The UFS, Stellenbosch University and the University of the Witwatersrand, form part of the COP which is a SARIMA (Southern African Research and Innovation Management Association) initiative to assist and share research ethics questions between institutions to empower research management and ethics compliance. SARIMA assisted with the online hosting and advertising of the webinar.

Purpose of the webinar

“Environment and Biosafety Committees in South Africa are a new idea, and only a few institutions in the country have such a committee. The UFS and the other institutions that will present at the workshop, take a leading role because they have already registered committees in place. We want to share and assist with establishing and operating such committees,” says Van Rooyen.

According to her, the need for the webinar arises from the upsurge of research and innovation in biotechnology and related fields over the past two decades that has led to exciting new discoveries in areas such as the engineering of biological processes, gene editing, stem cell research, CRISPR-Cas9 technology, Synthetic Biology, recombinant DNA, LMOs and GMOs, to mention only a few.

These advances, however, have generated concerns about biosafety, biosecurity and adverse impacts on biodiversity and the environment, leading to the establishment of Research Ethics Committees (RECs) at Higher Education and Research Institutions dedicated to reviewing research with implications for biosafety and the environment.

These EBRECs are in the early stages of their establishment and formalisation in South Africa, and there is much uncertainty about their composition, scope, procedures of decision-making and the principles that should guide their deliberations and assessments.

Leading the charge

The UFS took the lead in South Africa in ensuring international ethical compliance in this extended area of research, by establishing its own Environmental and Biological Research Ethics Committee (EBREC) six years ago. The UFS EBREC is one of only two such ethics committees at a South African university that combines the biosafety committee with environmental and biological research ethics to ensure ethics compliance in these fields.  The initiative started with Van Rooyen and her RIMS EthicsTeam, (Willem Kilian and Amanda Smith). The university is again taking charge with this webinar, which is a first of its kind.  

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept